Quick Answer
QIAGEN N.V. reported Total Revenue of $2.09 billion for fiscal year 2025.
QIAGEN N.V. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $2.09B +5.7% |
$1.98B +0.7% |
$1.97B -8.2% |
$2.14B -4.9% |
$2.25B +20.4% |
$1.87B +22.5% |
| Revenue (ASC 606) | $2.09B +5.7% |
$1.98B +0.7% |
$1.97B -8.2% |
$2.14B -4.9% |
$2.25B +20.4% |
$1.87B +22.5% |
| Net Income | $424.88M +408.3% |
$83.59M -75.5% |
$341.30M -19.4% |
$423.21M -17.4% |
$512.60M +42.7% |
$359.19M +966.5% |
| Diluted EPS | $1.94 +424.3% |
$0.37 -75.0% |
$1.48 -19.6% |
$1.84 -16.7% |
$2.21 +44.4% |
$1.53 +950.0% |
| Total Assets | $6.28B +10.4% |
$5.69B -7.0% |
$6.12B -2.7% |
$6.29B +2.3% |
$6.15B +4.7% |
$5.87B +12.1% |
| Cash and Equivalents | $839.00M +26.4% |
$663.55M -0.7% |
$668.08M -8.6% |
$730.67M -17.0% |
$880.52M +47.2% |
$597.98M -4.1% |
| Long-Term Debt | $1.65B +97.0% |
$839.66M -8.9% |
$921.82M -37.4% |
$1.47B +34.5% |
$1.09B -41.8% |
$1.88B +32.3% |
| Stockholders Equity | $3.78B +5.9% |
$3.57B -6.3% |
$3.81B +9.8% |
$3.47B +12.0% |
$3.10B +10.7% |
$2.80B +10.3% |
| Operating Income | $465.85M +376.8% |
$97.71M -76.2% |
$409.94M -22.9% |
$531.46M -15.7% |
$630.08M +63.1% |
$386.43M +1578.5% |
| Gross Profit | $1.30B +34.3% |
$967.35M -21.6% |
$1.23B -10.9% |
$1.38B -4.6% |
$1.45B +17.7% |
$1.23B +22.6% |
| Shares Outstanding | — | — | — | — | — | — |
- QIAGEN N.V. reported Total Revenue of $2.09 billion for fiscal year 2025.
- QIAGEN N.V. showed an increase of +5.7% in Total Revenue compared to the prior fiscal year.
- QIAGEN N.V. reported Revenue (ASC 606) of $2.09 billion for fiscal year 2025.
- QIAGEN N.V. showed an increase of +5.7% in Revenue (ASC 606) compared to the prior fiscal year.
- QIAGEN N.V. reported Net Income of $424.88 million for fiscal year 2025.
- QIAGEN N.V. showed an increase of +408.3% in Net Income compared to the prior fiscal year.
- QIAGEN N.V. reported Diluted EPS of $1.94 per share for fiscal year 2025.
- QIAGEN N.V. showed an increase of +424.3% in Diluted EPS compared to the prior fiscal year.
- QIAGEN N.V. reported Total Assets of $6.28 billion for fiscal year 2025.
- QIAGEN N.V. showed an increase of +10.4% in Total Assets compared to the prior fiscal year.
- QIAGEN N.V. reported Cash and Equivalents of $839.00 million for fiscal year 2025.
- QIAGEN N.V. showed an increase of +26.4% in Cash and Equivalents compared to the prior fiscal year.
- QIAGEN N.V. reported Long-Term Debt of $1.65 billion for fiscal year 2025.
- QIAGEN N.V. showed an increase of +97.0% in Long-Term Debt compared to the prior fiscal year.
- QIAGEN N.V. reported Stockholders Equity of $3.78 billion for fiscal year 2025.
- QIAGEN N.V. showed an increase of +5.9% in Stockholders Equity compared to the prior fiscal year.
- QIAGEN N.V. reported Operating Income of $465.85 million for fiscal year 2025.
- QIAGEN N.V. showed an increase of +376.8% in Operating Income compared to the prior fiscal year.
- QIAGEN N.V. reported Gross Profit of $1.30 billion for fiscal year 2025.
- QIAGEN N.V. showed an increase of +34.3% in Gross Profit compared to the prior fiscal year.
- QIAGEN N.V. reported Shares Outstanding of 236.49 million shares for fiscal year 2012.
- QIAGEN N.V. showed an increase of +1.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: